Science

Michael Duruisseaux: First effective targeted therapy in NRG1-fusion + solid tumors

Michael Duruisseaux/X

Feb 9, 2025, 15:33

Michael Duruisseaux: First effective targeted therapy in NRG1-fusion + solid tumors

Michael Duruisseaux, Physician-Scientist in the Onco-Pharmacology team at the Lyon Cancer Research Center, shared an article by Alison M. Schram, et al. on X:

“Hot of the press NEJM: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer | New England Journal of Medicine.

First effective targeted therapy in NRG1-fusion + solid tumors.

Very proud to collaborate to this study.”

Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer.

Authors: Alison M. Schram, et al.

Michael Duruisseaux: First effective targeted therapy in NRG1-fusion + solid tumors

Alison M. Schram cancer fight against cancer Global fight against cancer Lyon Cancer Research Center Michael Duruisseaux NEJM New England Journal of Medicine NRG1 fusion OncoDaily Oncology OncoPharmacology solid tumors zenocutuzumab

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Special Coverage